The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. This work was supported by the Paracelsus Medical University (PMU Grant: E13/17/089-MEG).
T.M, K.T., and A.E were primarily responsible for the drafting of manuscript. All authors were involved in the management of the patients, and wrote and critically revised the manuscript.
Morton LM, Wang SS, Devesa SS et al.. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265–276.
Zhou Z, Sehn LH, Rademaker AW et al.. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123:837–842.
Ziepert M, Hasenclever D, Kuhnt E et al.. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373–2380.
Melchardt T, Troppan K, Weiss L et al.. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and beta2-microglobulin. Br J Haematol 2015;168:239–245.
Eatrides J, Thompson Z, Lee JH et al.. Serum albumin as a stable predictor of prognosis during initial treatment in patients with diffuse large B cell lymphoma. Ann Hematol 2015;94:357–358.
Troppan K, Deutsch A, Gerger A et al.. The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Br J Cancer 2014;110:369–374.
Troppan KT, Schlick K, Deutsch A et al.. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. Br J Cancer 2014;111:55–60.
Yi JH, Wang D, Li ZY et al.. C-reactive protein as a prognostic factor for human osteosarcoma: a meta-analysis and literature review. PLoS One 2014;9:e94632.
Talaulikar D, Choudhury A, Shadbolt B, Brown M. Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas. Leuk Lymphoma 2008;49:959–964.
Troppan KT, Melchardt T, Deutsch A et al.. The significance of pre-treatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients [published online ahead of print February 13, 2015]. Eur J Haematol. doi: 10.1111/ejh.12529.
- Search Google Scholar
- Export Citation
. Troppan KT Melchardt T Deutsch A The significance of pre-treatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients [published online ahead of print February 13, 2015]. Eur J Haematol. doi: 10.1111/ejh.12529.
Moullet I, Salles G, Ketterer N et al.. Frequency and significance of anemia in non-Hodgkin‘s lymphoma patients. Ann Oncol 1998;9:1109–1115.
Boll B, Goergen H, Arndt N et al.. Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group. J Clin Oncol 2013;31:4431–4437.
Pathak S, Nunes QM, Daniels IR, Smart NJ. Is CRP useful in prognostication for colorectal cancer? A systematic review. Colorectal Dis 2014;16:769–776.
Dai J, Tang K, Xiao W et al.. Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis. Asian Pac J Cancer Prev 2014;15:3369–3375.
Porrata LF, Ristow K, Habermann T et al.. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol 2010;85:896–899.
Smith RA, Bosonnet L, Raraty M et al.. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009;197:466–472.
Smith RA, Ghaneh P, Sutton R et al.. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg 2008;12:1422–1428.
Smith RA, Bosonnet L, Ghaneh P et al.. The platelet-lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer. Surgery 2008;143:658–666.
Kwon HC, Kim SH, Oh SY et al.. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012;17:216–222.
Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S et al.. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol 2012;23:265–273.
Lee S, Oh SY, Kim SH et al.. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer 2013;13:350.
Segal I, Rassekh SR, Bond MC et al.. Abnormal liver transaminases and conjugated hyperbilirubinemia at presentation of acute lymphoblastic leukemia. Pediatr Blood Cancer 2010;55:434–439.
Ross WA, Egwim CI, Wallace MJ et al.. Outcomes in lymphoma patients with obstructive jaundice: a cancer center experience. Dig Dis Sci 2010;55:3271–3277.
Ghosh I, Bakhshi S. Jaundice as a presenting manifestation of pediatric non-Hodgkin lymphoma: etiology, management, and outcome. J Pediatr Hematol Oncol 2010;32:e131–135.
Sharma PB, Karki L. Abnormal hepatic function and splenomegaly on the newly diagnosed acute leukemia patients. JNMA J Nepal Med Assoc 2007;46:165–169.
Alizadeh AA, Eisen MB, Davis RE et al.. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
Barrans S, Crouch S, Smith A et al.. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28:3360–3365.
Ott G, Ziepert M, Klapper W et al.. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010;116:4916–4925.
Salles G, de Jong D, Xie W et al.. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011;117:7070–7078.
Choi WW, Weisenburger DD, Greiner TC et al.. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494–5502.
Hans CP, Weisenburger DD, Greiner TC et al.. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
Meyer PN, Fu K, Greiner TC et al.. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011;29:200–207.
Hu S, Xu-Monette ZY, Tzankov A et al.. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013;121:4021–4031.
- Search Google Scholar
- Export Citation
. Hu S Xu-Monette ZY Tzankov A MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013; 121: 4021– 4031.
Scott DW, Mottok A, Ennishi D et al.. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol 2015;33:2848–2856.
Cao Y, Shi YX, Chen JO et al.. Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumour Biol 2012;33:1039–1044.
Giachelia M, Voso MT, Tisi MC et al.. Interleukin-6 plasma levels are modulated by a polymorphism in the NF-kappaB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2012;53:411–416.
- Search Google Scholar
- Export Citation
. Giachelia M Voso MT Tisi MC Interleukin-6 plasma levels are modulated by a polymorphism in the NF-kappaB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2012; 53: 411– 416.